241 related articles for article (PubMed ID: 16329044)
21. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
[TBL] [Abstract][Full Text] [Related]
22. [Study of differential gene expression in different stage human endometrial cancer].
Wan XP; Cai B; Liu L; Xi XW; Yang YX
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):38-42. PubMed ID: 16635327
[TBL] [Abstract][Full Text] [Related]
23. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
24. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiles of benign and (pre)malignant endometrial lesions.
van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
[TBL] [Abstract][Full Text] [Related]
27. Genetic and epigenetic alterations in precursor lesions of endometrial endometrioid carcinoma.
Gotoh O; Sugiyama Y; Tonooka A; Kosugi M; Kitaura S; Minegishi R; Sano M; Amino S; Furuya R; Tanaka N; Kaneyasu T; Kumegawa K; Abe A; Nomura H; Takazawa Y; Kanao H; Maruyama R; Noda T; Mori S
J Pathol; 2024 Jul; 263(3):275-287. PubMed ID: 38734880
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors.
Huvila J; Brandt A; Rojas CR; Pasanen S; Talve L; Hirsimäki P; Fey V; Kytömäki L; Saukko P; Carpén O; Soini JT; Grénman S; Auranen A
Int J Gynecol Cancer; 2009 Oct; 19(7):1226-31. PubMed ID: 19823059
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
30. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
Turbiner J; Moreno-Bueno G; Dahiya S; Sánchez-Estevez C; Hardisson D; Prat J; Oliva E; Palacios J
Mod Pathol; 2008 Aug; 21(8):925-36. PubMed ID: 18500270
[TBL] [Abstract][Full Text] [Related]
32. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
33. Theories of endometrial carcinogenesis: a multidisciplinary approach.
Sherman ME
Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
[TBL] [Abstract][Full Text] [Related]
34. Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma.
Liu T; Willmore-Payne C; Wallander ML; Layfield LJ
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):341-6. PubMed ID: 21285871
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
36. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
37. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I; Ali S; Lankes HA; Backes F; Moore K; Mutch D; Robison K; Behbakht K; Waggoner S; Ghebre RG; Pearl M; Ramirez NC; Goodfellow P
Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
[TBL] [Abstract][Full Text] [Related]
38. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations in endometrial cancers: relation to PTEN gene defects.
Janiec-Jankowska A; Konopka B; Goluda C; Najmoła U
Int J Gynecol Cancer; 2010 Feb; 20(2):196-202. PubMed ID: 20169661
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
